Stock Watch: Biotechs Sell The Family Silver

But Are They Just Delaying The Inevitable?

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

I took the decision recently to take profits from much of my exposure to biotech companies in the exchange-traded funds that are based on the NASDAQ Biotech Index (NBI). When I made these investments a few years ago the NBI was about 30% below its last peak in August 2021. I had hoped that the stock prices of the sector’s companies would rally more as the cumulative positives of the NBI’s constituents being acquired by big pharma companies and their clinical and regulatory successes were all recognized.

While some of this has happened for antibody-drug conjugate and radiopharmaceutical companies, the recognition of the sector by generalist investors...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.